The Lancet Infectious Diseases, volume 15, issue 9, pages 1091-1099

Para-aminosalicylic acid: the return of an old friend

Publication typeJournal Article
Publication date2015-09-01
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor56.3
ISSN14733099, 14744457
Infectious Diseases
Abstract
Para-aminosalicylic acid (PAS) is one of the last remaining drugs available to treat extensively drug-resistant (XDR) tuberculosis. Good outcomes (81% 5 year survival) were documented when PAS was first used with streptomycin, yet results of PAS with remaining potentially effective drugs for the treatment of XDR tuberculosis are poor (mortality 30-90%). In this Review, we assess published work regarding recommendations for PAS dosing in relation to efficacy and tolerance. PAS 20 g daily acoompanied only by streptomycin is better in prevention of streptomycin resistance than PAS 10 g or 5 g daily. When accompanied by isonazid, a more potent drug than streptomycin, treatment success with PAS 20 g daily is similar to that of PAS 10 g daily. In contemporary, relatively weak XDR tuberculosis regimens, the recommended doseage of PAS 8-12 g in two to three doses daily is probably insufficient. Furthermore, once daily PAS could be considered, because substantial research suggests no worse intolerance than with multiple daily PAS doses. In most countries, PAS is now available in a granular, slow-release formulation that seems well tolerated, but efficacy has never been formally assessed. Once daily dosing with granular PAS might achieve high peak concentrations and a long interval above minimum inhibitory concentration, with the advantage of improved supervision of drug intake.

Top-30

Citations by journals

1
2
3
Antimicrobial Agents and Chemotherapy
3 publications, 6.98%
European Journal of Clinical Pharmacology
2 publications, 4.65%
International Journal of Pharmaceutics
2 publications, 4.65%
The Lancet Infectious Diseases
2 publications, 4.65%
American Journal of Respiratory and Critical Care Medicine
1 publication, 2.33%
Mini-Reviews in Medicinal Chemistry
1 publication, 2.33%
Pharmaceutics
1 publication, 2.33%
Frontiers in Cellular and Infection Microbiology
1 publication, 2.33%
Journal of Molecular Modeling
1 publication, 2.33%
Scientific Reports
1 publication, 2.33%
International Journal of Antimicrobial Agents
1 publication, 2.33%
Journal of Molecular Graphics and Modelling
1 publication, 2.33%
The Lancet Respiratory Medicine
1 publication, 2.33%
Journal of Separation Science
1 publication, 2.33%
ChemistrySelect
1 publication, 2.33%
Journal of Clinical Pharmacology
1 publication, 2.33%
British Journal of Clinical Pharmacology
1 publication, 2.33%
Journal of Medicinal Chemistry
1 publication, 2.33%
Expert Opinion on Drug Safety
1 publication, 2.33%
Expert Opinion on Pharmacotherapy
1 publication, 2.33%
Expert Opinion on Drug Metabolism and Toxicology
1 publication, 2.33%
Journal of Antimicrobial Chemotherapy
1 publication, 2.33%
Lung India
1 publication, 2.33%
AIP Conference Proceedings
1 publication, 2.33%
Biomaterials Science
1 publication, 2.33%
ACS Infectious Diseases
1 publication, 2.33%
Expert Review of Clinical Pharmacology
1 publication, 2.33%
Pharmaceuticals
1 publication, 2.33%
Clinical Microbiology Reviews
1 publication, 2.33%
1
2
3

Citations by publishers

2
4
6
8
10
Elsevier
10 publications, 23.26%
Taylor & Francis
6 publications, 13.95%
Springer Nature
5 publications, 11.63%
Wiley
4 publications, 9.3%
American Society for Microbiology
4 publications, 9.3%
Multidisciplinary Digital Publishing Institute (MDPI)
2 publications, 4.65%
American Chemical Society (ACS)
2 publications, 4.65%
American Thoracic Society
1 publication, 2.33%
Bentham Science
1 publication, 2.33%
Frontiers Media S.A.
1 publication, 2.33%
Oxford University Press
1 publication, 2.33%
Wolters Kluwer Health
1 publication, 2.33%
American Institute of Physics (AIP)
1 publication, 2.33%
Royal Society of Chemistry (RSC)
1 publication, 2.33%
Cold Spring Harbor Laboratory
1 publication, 2.33%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 2.33%
2
4
6
8
10
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Donald P. R., Diacon A. Para-aminosalicylic acid: the return of an old friend // The Lancet Infectious Diseases. 2015. Vol. 15. No. 9. pp. 1091-1099.
GOST all authors (up to 50) Copy
Donald P. R., Diacon A. Para-aminosalicylic acid: the return of an old friend // The Lancet Infectious Diseases. 2015. Vol. 15. No. 9. pp. 1091-1099.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/s1473-3099(15)00263-7
UR - https://doi.org/10.1016/s1473-3099(15)00263-7
TI - Para-aminosalicylic acid: the return of an old friend
T2 - The Lancet Infectious Diseases
AU - Donald, Peter R.
AU - Diacon, A
PY - 2015
DA - 2015/09/01 00:00:00
PB - Elsevier
SP - 1091-1099
IS - 9
VL - 15
SN - 1473-3099
SN - 1474-4457
ER -
BibTex |
Cite this
BibTex Copy
@article{2015_Donald,
author = {Peter R. Donald and A Diacon},
title = {Para-aminosalicylic acid: the return of an old friend},
journal = {The Lancet Infectious Diseases},
year = {2015},
volume = {15},
publisher = {Elsevier},
month = {sep},
url = {https://doi.org/10.1016/s1473-3099(15)00263-7},
number = {9},
pages = {1091--1099},
doi = {10.1016/s1473-3099(15)00263-7}
}
MLA
Cite this
MLA Copy
Donald, Peter R., and A Diacon. “Para-aminosalicylic acid: the return of an old friend.” The Lancet Infectious Diseases, vol. 15, no. 9, Sep. 2015, pp. 1091-1099. https://doi.org/10.1016/s1473-3099(15)00263-7.
Found error?